With an estimated 12,600 new cases of bladder cancer in Canada in 2025, plus almost 84,870 in the United States, ranking 5th ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

Blue Earth Therapeutics today announced that the first patients in the UK have been administered with the investigational ...

A new report shows the five-year survival rate for all cancers reached a historic 70%. About 2.1 million new cancer diagnoses ...